Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw's Annual Healthcare Conference in New York.CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. to Highlight Proprietary Embryonic Stem Cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. Technology Platforms and Continued Development of Therapeutic Initiatives ALAMEDA, Calif. -- Advanced Cell Technology (ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ), Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACTC), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that Chief Executive Officer, William M. Caldwell, IV will be a featured presenter at Rodman & Renshaw's 8th Annual Healthcare Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on November 6-8. Mr. Caldwell will review ACTC's proprietary technologies and recent milestones in its mission to drive medically needed stem cell-based therapies to the clinic. He will discuss ACTC's stem cell-related technology platforms, and will spotlight the company's lead programs to develop novel stem cell therapies stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs in the fields of vision, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. wound repair for scarless healing from burns, surgery and other causes. ACTC's recent milestones include publication of the company's single cell blastomere blastomere /blas·to·mere/ (blas´to-mer) one of the cells produced by cleavage of a zygote. blas·to·mere n. technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The Company also recently published positive progress in its retinal pigment epithelial (RPE RPE Retinal Pigment Epithelium RPE Rating of Perceived Exertion (exercise) RPE Respiratory Protective Equipment RPE Regular Pulse Excitation RPE Registered Professional Engineer RPE Rapid Palatal Expansion ) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina. The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries. The conference will take place at the Palace Hotel at 455 Madison Ave., in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY. The ACTC presentation is scheduled for 11:40 AM in the Kennedy II room, 4th floor. A live audio webcast can be accessed on the date of the presentation at www.advancedcell.com, and will be archived for 90 days. A downloadable copy of the presentation will also be available on the company's website at www.advancedcell.com/conference-presentations/. For more information about the Rodman & Renshaw conference, visit http://www.rodmanandrenshaw.com. About Advanced Cell Technology, Inc. Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information, please visit: www.advancedcell.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/advanced_cell. To read or download Advanced Cell's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/advanced_cell/factsheet.html. To view recent stock quotes and news, visit http://www.trilogy-capital.com/tcp/advanced_cell/quote.html. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion